Birgitte Rønø is the current Chief Scientific Officer at Evaxion Biotech. Prior to their current position, they worked as a Specialist for Diabetes Complication Research at Novo Nordisk from March 2013 to April 2017. During their time at Novo Nordisk, they were responsible for outlining, driving and implementing a pre-clinical strategy within the disease area. Additionally, they were a member of a cross-functional target innovation team and managed discovery projects. Some of their key achievements include project endorsement from top management and the implementation of a pre-clinical strategy for Diabetes Complication Research.